Experiment Biotechnology With Chemistry Science on Feature Quote
About Us

Specialists in Nucleic Acids

As a raw materials supplier as well as a specialist CDMO in the RNA industry, we provide high-quality products and services with best-in-class lead times and price. 

A team with extensive experience in the RNA industry

Our desire and ability to continuously innovate is fueled by a team of world-class scientists. We have a diverse team of over 1,600 professionals across the globe and a dedicated R&D team comprising 400 experts, committed to impacting the nucleic acid sector through innovation.

A Pioneer Mind

Specializing in nucleosides, nucleotides, and phosphoramidites, we have developed a world-renowned level of expertise. By working with Hongene, your nucleic acids will get the care and attention of some of the world's best.

Our Partnerships

We are proud to be a member of The Alliance for mRNA Medicines and support a number of non-profit organizations that are dedicated to the development of drugs for rare diseases and cancers using mRNA and oligonucleotide modalities.


David Butler

Chief Technology Officer
Chin400v2 (1)

KS Chin

SVP, Global Business Development
David Pic3

David Yu

VP, US Scientific Operations and Business Development
Michael 400

Michael Leuck

VP, European Market
Yanshengv2 02 (1)

Yansheng Wu

VP, Global Head of CMC & Regulatory

The Future

Company founded

Hongene Biotech was founded in 1998, as one of the earliest companies working in the nucleic acid industry.

Gene 1
Achieved kg scale phosphoramidites

A significant milestone for Hongene Biotech in achieving kg scale phosphoramidites manufacturing capability.

Doctor 563429 1280
mRNA company collaboration

Hongene's first collaboration with customers in the mRNA field.

D Koi 5Ni9n2wncbu Unsplash
Manufacturing facility No.1 construction completed

Raw material manufacturing facility (no.1) completed construction with large-scale manufacturing capability

Began cap analog production

Hongene was one of the earliest companies manufacturing cap analogs.

Opened new R&D center in California

To strengthen our technological innovation capabilities, Hongene established a new R&D center in Union City, San Francisco.

Manufacturing facility No.2 completed construction

Hongene's new manufacturing facility launched operation with 50 tons of phosphoramidites and 36,000 liters of NTP production capacity.

Key raw materials supplier for mRNA Covid-19 vaccine during the pandemic

Hongene made a significant contribution to fight against the Covid-19 by supplying a large amount of raw materials used in mRNA vaccine.

Delivered 1st mRNA Covid-19 vaccine CDMO project

Hongene collaborated with top vaccine companies and delivered mRNA COVID-19 omicron and bivalent vaccine CDMO projects. 

Fusion Medical Animation Rnr8d3fnuny Unsplash
Construct a new manufacturing facility in Hungary

To offer clients with a more secure global supply chain, Hongene launched its new facility construction in Hungary.

Cdc Cfs6a4u5g8m Unsplash

Hybrid Synthesis

未标题 1

Super Pure RNA 

N Lorem Vertical Logo

n-Lorem Foundation

n-Lorem is focused on discovering, developing, and providing personalized experimental ASO medicines, for free, for life, to patients with nano-rare diseases caused by a single gene defect that affects one person or, at most, 30 patients worldwide.

N=1 画板 2

N=1 Collaborative

N=1 Collaborative is a group of internationally acclaimed doctors, researchers, patients and companies from across the globe who are committed to expanding the field of individualized medicine.


The Alliance for mRNA Medicines (AMM)

The Alliance for mRNA Medicines (AMM) is the leading global organization dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines for the benefit of patients, public health, and society.